Chlorpromazine: A Comprehensive Review of Its Pharmacology, Clinical Use, and Safety Profile

When a 45‑year‑old male presents to the emergency department with acute psychosis and violent agitation, the clinician’s first instinct may be to administer a rapidly acting antipsychotic. While newer agents are often favored, chlorpromazine remains a cornerstone in certain settings—particularly in resource‑limited environments, as an adjunct in severe agitation, and for its broad spectrum of off‑label indications. Historically, chlorpromazine heralded the era of modern psychopharmacology, and its continued use underscores the importance of understanding its unique pharmacology, safety profile, and clinical nuances.

Introduction and Background

Chlorpromazine (CPZ), first synthesized in 1950 by Paul Charpentier and later introduced clinically in 1952, is the prototype of the typical antipsychotics. It was the first drug to demonstrate a clear therapeutic effect in schizophrenia, fundamentally changing psychiatric treatment. The drug’s discovery was serendipitous: Charpentier was investigating antihistamines when he noted the antipsychotic effect of a chlorinated derivative in a patient with psychosis.

CPZ belongs to the phenothiazine class, characterized by a tricyclic core structure with a side chain that confers receptor affinity. Its pharmacological activity is broad, targeting dopamine D2, histamine H1, adrenergic α1, muscarinic M1, and serotonin 5‑HT2 receptors. This multi‑receptor blockade underlies both its therapeutic efficacy in psychosis and its propensity for side effects. Epidemiologically, CPZ remains widely prescribed in many countries, especially where cost constraints limit access to newer atypical agents. Despite the advent of second‑generation antipsychotics, CPZ is still recommended as a first‑line agent in certain acute agitation protocols and for specific off‑label uses such as nausea, vomiting, and certain movement disorders.

In the context of chronic schizophrenia, CPZ’s long half‑life and high potency at D2 receptors make it effective for symptom control, but its side effect burden necessitates careful monitoring. The drug’s historical significance and continued clinical relevance make it a vital topic for both clinicians and pharmacology students.

Mechanism of Action

Dopamine D2 Receptor Antagonism

CPZ’s primary antipsychotic effect stems from high‑affinity antagonism of dopamine D2 receptors in the mesolimbic pathway. By competitively inhibiting dopamine binding, CPZ reduces positive psychotic symptoms such as hallucinations and delusions. The drug’s affinity for D2 is among the highest in the phenothiazine class, which also contributes to its potency at lower doses.

Histamine H1 Receptor Blockade

Strong H1 antagonism accounts for CPZ’s sedative properties and its utility in acute agitation. The blockade reduces histamine release, leading to decreased neuronal excitability and a calming effect. Clinically, this explains the drug’s rapid onset of sedation when administered intravenously.

Adrenergic α1 Receptor Antagonism

CPZ’s α1 blockade produces vasodilation, resulting in orthostatic hypotension, especially after the first dose. This effect is mediated by inhibition of norepinephrine release and direct receptor antagonism, leading to decreased peripheral vascular resistance.

Muscarinic M1 and Serotonin 5‑HT2 Receptor Antagonism

Antagonism at M1 receptors underlies anticholinergic side effects such as dry mouth, blurred vision, and constipation. CPZ’s 5‑HT2 blockade contributes to its antiemetic properties and may mitigate extrapyramidal symptoms (EPS) by balancing dopaminergic activity in the nigrostriatal pathway.

Clinical Pharmacology

Chlorpromazine is administered orally, intramuscularly, or intravenously, with the latter two routes reserved for acute agitation. The drug demonstrates dose‑dependent plasma concentration increases, but saturation occurs at higher doses due to limited absorption.

Pharmacokinetics: Oral bioavailability averages 20–30% due to first‑pass hepatic metabolism. Peak plasma concentrations (Cmax) are reached within 2–3 hours (Tmax). The elimination half‑life ranges from 5–10 hours, extending to 15–20 hours in patients with hepatic impairment. CPZ is highly protein‑bound (~95%), primarily to albumin. Metabolism occurs via hepatic CYP2D6 and CYP3A4, producing active metabolites such as norchlorpromazine. Excretion is predominantly renal (70–80%) with the remainder eliminated via bile.

Pharmacodynamics: The therapeutic dose range for chronic schizophrenia is 200–800 mg/day divided into 3–4 doses. The dose–response curve is steep; small increases can lead to significant side effect escalation. Therapeutic plasma levels typically fall between 100–200 ng/mL, though individual variability is high.

Therapeutic Applications

• Schizophrenia (chronic and acute)
• Acute agitation and delirium (IV or IM)
• Psychotic depression (adjunct)
• Severe nausea and vomiting (IV)
• Certain movement disorders (e.g., tardive dyskinesia, dystonia) as adjunct
• Adjunct for opioid withdrawal symptoms

FDA‑approved dosing for schizophrenia starts at 200 mg/day, titrated up to 800 mg/day as needed. For acute agitation, IV loading doses of 50–100 mg are followed by maintenance of 25–50 mg every 6–8 hours. Off‑label uses, such as antiemetic therapy, employ lower doses (25–50 mg IV). In pediatric populations, dosing is weight‑based: 2–4 mg/kg/day for psychosis, capped at 200 mg/day. Geriatric patients require lower initial doses (50–100 mg/day) due to increased sensitivity to orthostatic hypotension and extrapyramidal side effects. Renal or hepatic impairment necessitates dose adjustments; for mild hepatic dysfunction, a 25% dose reduction is advised. Pregnancy category C; use only when benefits outweigh risks, preferably after the first trimester.

Adverse Effects and Safety

Common side effects and approximate incidence:

• Orthostatic hypotension – 30–50%
• Drowsiness – 40–60%
• Extrapyramidal symptoms (EPS) – 20–30%
• Anticholinergic effects (dry mouth, blurred vision) – 15–25%
• Weight gain – 10–20% over 6 months
• Neuroleptic malignant syndrome (NMS) – <0.1%

Black box warning: NMS and tardive dyskinesia. Clinicians must monitor for fever, rigidity, altered mental status, and autonomic instability. Regular assessment of orthostatic vital signs, extrapyramidal scales, and metabolic panels is recommended.

Clinical Pearls for Practice

• Start low, go slow: Begin at 50 mg/day for elderly or first‑time users; titrate by 50 mg increments every 3–5 days.
• Watch orthostatic hypotension: Perform standing BP checks after the first dose and after any dose increase.
• Identify NMS early: Look for fever, rigidity, autonomic instability; discontinue CPZ immediately if suspected.
• Use the “C‑H‑A‑S” mnemonic: C‑orthostatic hypotension, H‑sedation, A‑EPS, S‑serotonin interactions.
• Consider weight gain: Counsel patients on diet and exercise; monitor BMI quarterly.
• Avoid concomitant CNS depressants: Alcohol, benzodiazepines, or opioids can potentiate sedation and respiratory depression.
• Use IV for agitation: A 50 mg IV dose provides rapid sedation; monitor for hypotension and respiratory status.

Comparison Table

Exam‑Focused Review

Common exam question stems:

• “A 32‑year‑old man with schizophrenia presents with severe agitation. Which drug should be administered first‑line for rapid sedation?”
• “A patient on chlorpromazine develops sudden fever, rigidity, and autonomic instability. What is the most likely diagnosis?”
• “Which of the following side effects is most associated with phenothiazines?”

Key differentiators students often confuse:

• Orthostatic hypotension (typical antipsychotics) vs. QT prolongation (some atypicals).
• EPS (typicals) vs. metabolic syndrome (atypicals).
• High protein binding leading to drug–drug interactions.

Must‑know facts for NAPLEX/USMLE/clinical rotations:

• Chlorpromazine’s high affinity for D2 receptors accounts for its potency.
• Its α1 blockade causes orthostatic hypotension, making it unsuitable for patients on antihypertensives.
• Neuroleptic malignant syndrome is a medical emergency; discontinue CPZ immediately and administer dantrolene or bromocriptine.
• Use weight‑based dosing in pediatrics; cap at 200 mg/day.
• Monitor serum prolactin if patient reports galactorrhea or amenorrhea.

Key Takeaways

1. Chlorpromazine is a phenothiazine with multi‑receptor blockade (D2, H1, α1, M1, 5‑HT2).
2. Its therapeutic range is 200–800 mg/day; start low in elderly or first‑time users.
3. Orthostatic hypotension is the most common adverse effect; monitor blood pressure after each dose increase.
4. Neuroleptic malignant syndrome, though rare, requires immediate discontinuation and supportive care.
5. Use IV or IM routes for rapid sedation in acute agitation; avoid concomitant CNS depressants.
6. Drug interactions: potentiation with cardiac glycosides, serotonin syndrome with SSRIs, additive hypotension with antihypertensives.
7. Weight gain and metabolic effects are less pronounced than with atypical antipsychotics but still significant.
8. In pregnancy, use only when benefits outweigh risks; monitor fetal development.
9. Comparative pharmacokinetics: CPZ has low bioavailability and high protein binding; other antipsychotics differ in half‑life and metabolism.
10. Clinical pearls: “C‑H‑A‑S” mnemonic aids recall of major side effects.

Always weigh the benefits of chlorpromazine against its side‑effect profile, especially orthostatic hypotension and EPS, and tailor dosing to individual patient characteristics.